AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2017
Oct 16, 2017
31523_dirs_2017-10-16_dc08c431-5e88-4d86-a72a-70b0710d6888.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2017-10-12
Reporting Person: Quimi Daphne (SVP, Finance)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-10-12 | Common stock | M | 7000 | $14.2485 | Acquired | 61676 | Direct |
| 2017-10-12 | Common stock | S | 7000 | $14.2485 | Disposed | 54676 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-10-12 | Stock Options (right to buy) | $10.21 | M | 7000 | Disposed | 2018-02-05 | Common stock (7000) | Direct |
Footnotes
F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017.
F2: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.10 to $14.43. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F3: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.10 to $14.43. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.